Electronic Study for Anastrozole Pharmacovigilance Evaluation (E-SAFE)

AstraZeneca

Status: Completed

Conditions: Early Breast Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT00558168

ARI-IPEP-0104

Details and patient eligibility

About

Collecting information regarding adverse events from patients on treatment with anastrazole with early stage breast cancer

Enrollment: 1,850 patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• Post-menopausal Early Invasive Breast Cancer Patients who are under anastrazole treatment, who have normal renal and hepatic functions.

Exclusion criteria

• Metastatic breast cancer patients, previous hormonal therapy, other malignancies.